Precision Business Insights
Portfolio

 

Research Reports

Sickle Cell Disease Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Sickle Cell Disease Treatment Market

 

Drastic reduction of total RBC count is called as anaemia. It is also defined as the inability of carrying the appropriate amounts of oxygen by blood. Sickle cell diseases are the type of blood disorders which are genetically inherited. Sickle-cell anaemia is the common type of SCD in which sickle-shaped cell is formed. Generally, sickle cell disease starts taking shape at the early age i.e., within a year after birth which leads to several health issues like attacks of pain which are also called as the sickle-cell crisis, limbs swelling, bacterial infections etc. Chronic pain can be developed along with the age. Sickle-cell diseases arise when an individual inherited by abnormal copies of Hg gene from each parent.

 

Sickle Cell Diseases Treatment Market is driven by the increasing prevalence of sickle cell anaemia in the developed, developing as well as underdeveloped economies. In addition to this unmet needs are highly available, a rise in product pipelines for the treatment of SCD is anticipated to pose great demand for the market. Sickle cell disease treatment market is propelled by rising support by the regulatory bodies and government in the form of investments, fast-track approvals for the discovery of newer treatments. Sickle cell anaemia treatment market is restrained by slow adoption of treatments due to the cost associated with it, the absence of a permanent cure for this disease and complications associated with treatment.

 

Sickle Cell Diseases Treatment Market is segmented on the basis of disease type, therapy, drug class, distribution channel, and geography.

 

On the basis of disease type, the global Sickle Cell Diseases Treatment Market treatment is segmented as:

  • Sickle Beta Thalassemia
  • Sickle Haemoglobin C Disease
  • Sickle Cell Anaemia
  • Others

 

On the basis of therapy, the global Sickle Cell Diseases Treatment Market is segmented as:

  • Bone Marrow Transplant
  • Blood Transfusion
  • Gene Therapy

 

On the basis of the drug class, the global Sickle Cell Diseases Treatment Market is segmented as:

  • Antibiotics
  • Analgesics
  • Antimetabolite (Hydroxyurea)
  • Others

 

On the basis of the end user, the global Sickle Cell Diseases Treatment Market is segmented as:

  • Hospitals
  • Retail Pharmacies
  • Others

 

Burgeoning prevalence of sickle cell disease has expected to drive the market. As per Centre for Disease Control and Prevention, in 2016, about 100,000 individuals in U.S. are affected by the sickle cell diseases. Black or the African Americans are commonly more susceptible to sickle cell diseases. One in thirteen babies who belongs to the black race are born with SCD’s. Researchers have moved ahead to treat SCD by antibiotics to genome level. Researchers from the Stanford School of Medicine corrected the genes successfully which are carrying a gene for SCD and transplanted them with the healthy cells. With the help of Clustered Regularly Interspaced Short Palindromic Repeat technique (CRISPR), researchers have replaced the SCD cell genes with one which doesn’t carry those genes. In 2016, Infosys has donated USD 1.11 million for the stem cell research to develop gene therapies for the disorders like haemophilia and sickle cell disease.

 

Based on the geographical regions, a global Sickle Cell Diseases Treatment Market is segmented into Latin America, Europe, North America, the Middle East and Africa, and Asia Pacific. North America is dominating the sickle cell anaemia treatment market due to the increase in activities in R&D, high accessibility of developed healthcare infrastructure and high reimbursement policies are attributing for the growth of the SCD treatment market in the region. Owing to the high prevalence rate of disease in Asia Pacific and African regions is favouring the growth of SCD treatment market. Asia-Pacific is one of the speedy growing markets due to the funding of the various industry players for stem cell research

 

Some of the sickle cell disease treatment providers are Biogen (U.S.), Gamida Cell (Israel), Genetix Pharmaceuticals Inc. (U.S.), Sangamo Biosciences (U.S.), Alnylam Pharmaceuticals, Inc. (U.S.), Acceleron Pharma (U.S.), Global Blood Therapeutics Inc. (U.S.), Emmaus Medical, Inc. (U.S.), Novartis AG (Switzerland) and Bristol-Myers Squibb Company (U.S.).

 

  • In July 2017, Emmaus Medical Inc. Endari (L-glutamine oral powder) received U.S. FDA approval to treat the patients with age of five years and older having sickle cell disease

 

  • In 2016 Novartis AG acquired Selexys Pharmaceuticals in order to expand product offerings related to blood disorders and diseases

 

Report Outline:

 

  • The report provides granular level information about the market size, regional market share and forecast from 2017-2023
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  1. Executive summary
  2. Global Sickle Cell Disease Treatment Market Introduction
    • Global Sickle Cell Disease Treatment Market– Taxonomy
    • Global Sickle Cell Disease Treatment Market–Definitions
      • Disease Type
      • Therapy
  1. Global Sickle Cell Disease Treatment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Sickle Cell Disease Treatment Market Dynamics – Factors Impact Analysis
    • Global Sickle Cell Disease Treatment Market– Recent Market Introductions
  2. Global Sickle Cell Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Oppurtunity Analysis
  3. Global Sickle Cell Disease Treatment Market Forecast, By Diseases Type, 2013 – 2017 and Forecast, 2018 – 2024
    • Sickle Beta Thalassemia
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Sickle Haemoglobin C Disease
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Sickle Cell Anaemia
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Sickle Cell Disease Treatment Market Forecast, By Therapy, 2013 – 2017 and Forecast, 2018 – 2024
    • Bone Marrow Transplant
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Blood Transfusion
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Gene Therapy
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Sickle Cell Disease Treatment Market Forecast, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024
    • Antibiotics
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Analgesics
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Antimetabolites
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Sickle Cell Disease Treatment Market Forecast, By End User, 2013 – 2017 and Forecast, 2018 – 2024
    • Hospitals
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Sickle Cell Disease Treatment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024
    • North America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Sickle Cell Disease Treatment Market- Opportunity Analysis Index – By Diseases Type, By Therapy, By Drug Class, By End User, and Region, 2018 – 2024
  2. North America Sickle Cell Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Diseases Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Sickle Beta Thalassemia
      • Sickle Haemoglobin C Disease
      • Sickle Cell Anaemia
      • Others
    • Therapy Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Bone Marrow Transplant
      • Blood Transfusion
      • Gene Therapy
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Antibiotics
      • Analgesics
      • Antimetabolite (Hydroxyurea)
      • Others
    • End User Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospitals
      • Diagnostic Centres
      • Blood Donation Centres
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • S.
      • Canada
    • North America Sickle Cell Disease Treatment Market- Opportunity Analysis Index – By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2018 – 2024
    • North America Sickle Cell Disease Treatment Market Dynamics – Trends
  3. Europe Sickle Cell Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Diseases Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Sickle Beta Thalassemia
      • Sickle Haemoglobin C Disease
      • Sickle Cell Anaemia
      • Others
    • Therapy Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Bone Marrow Transplant
      • Blood Transfusion
      • Gene Therapy
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Antibiotics
      • Analgesics
      • Antimetabolite (Hydroxyurea)
      • Others
    • End User Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospitals
      • Diagnostic Centres
      • Blood Donation Centres
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Sickle Cell Disease Treatment Market- Opportunity Analysis Index – By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2018 – 2024
    • Europe Sickle Cell Disease Treatment Market Dynamics – Trends
  4. Asia-Pacific Sickle Cell Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Diseases Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Sickle Beta Thalassemia
      • Sickle Haemoglobin C Disease
      • Sickle Cell Anaemia
      • Others
    • Therapy Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Bone Marrow Transplant
      • Blood Transfusion
      • Gene Therapy
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Antibiotics
      • Analgesics
      • Antimetabolite (Hydroxyurea)
      • Others
    • End User Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospitals
      • Diagnostic Centres
      • Blood Donation Centres
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn),
  5. Y-o-Y Growth (%), and Market Share (%)
    • Japan
    • China
    • India
    • ASEAN
    • Australia & New Zealand
    • Rest of Asia-Pacific
  • Asia-Pacific Sickle Cell Disease Treatment Market- Opportunity Analysis Index – By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2018 – 2024
  • Asia-Pacific Sickle Cell Disease Treatment Market Dynamics – Trends
  1. Latin America Sickle Cell Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Diseases Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Sickle Beta Thalassemia
      • Sickle Haemoglobin C Disease
      • Sickle Cell Anaemia
      • Others
    • Therapy Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Bone Marrow Transplant
      • Blood Transfusion
      • Gene Therapy
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Antibiotics
      • Analgesics
      • Antimetabolite (Hydroxyurea)
      • Others
    • End User Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospitals
      • Diagnostic Centres
      • Blood Donation Centres
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Sickle Cell Disease Treatment Market- Opportunity Analysis Index – By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2018 – 2024
    • Latin America Sickle Cell Disease Treatment Market Dynamics – Trends
  2. Middle East & Africa Sickle Cell Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Diseases Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Sickle Beta Thalassemia
      • Sickle Haemoglobin C Disease
      • Sickle Cell Anaemia
      • Others
    • Therapy Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Bone Marrow Transplant
      • Blood Transfusion
      • Gene Therapy
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Antibiotics
      • Analgesics
      • Antimetabolite (Hydroxyurea)
      • Others
    • End User Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospitals
      • Diagnostic Centres
      • Blood Donation Centres
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Sickle Cell Disease Treatment Market- Opportunity Analysis Index – By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2018 – 2024
    • MEA Sickle Cell Disease Treatment Market Dynamics – Trends
  3. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Biogen (U.S.)
      • Gamida Cell (Israel)
      • Genetix Pharmaceuticals Inc. (U.S.)
      • Sangamo Biosciences (U.S.)
      • Alnylam Pharmaceuticals, Inc. (U.S.)
      • Acceleron Pharma (U.S.)
      • Global Blood Therapeutics Inc. (U.S.)
      • Emmaus Medical, Inc. (U.S.)
      • Novartis AG (Switzerland)
      • Bristol-Myers Squibb Company (U.S.).
  4. Research Methodology
  5. Key Assumptions and Acronyms

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

OR

CALL US ON : 123456789

Select License Type

Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner
FacebookTwitterLinkedinEmail

Our Clients

Testimonials

Contact SalesTOLL FREE: +1-866-598-1553